Michael Jackson, PhD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Michael L. Jackson, PhD, MPH

Group Health Research Institute Assistant Investigator


Michael L. Jackson’s research focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal investigator for the United States Influenza Vaccine Effectiveness Network. This Network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this Network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies. He also uses mathematical models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenza type b (Hib) and Neisseria meningitidis.

Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and  Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the  safety of childhood immunizations and develops methods for using managed care  data for vaccine safety studies.

While studying for his PhD at the University of  Washington, Dr. Jackson was a graduate research associate with GHRI from 2002 to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib  disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to GHRI as an assistant investigator in 2010.

Research interests and experience




Recent publications

Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham TC, Naleway A, Omer SB, Hambidge SJ, Lee GM, Jackson ML, McCarthy NL, DeStefano F, Nordin JD.

Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes.

JAMA. 2014;312(18):1897-904. doi: 10.1001/jama.2014.14825. PubMed

Jackson ML.

Influenza vaccine effectiveness in elderly people.

Lancet Infect Dis. 2014 12(14):1169-70. doi:10.1016/S0140-6736(08)61345-8.

Havers F, Thaker S, Clippard JR, Jackson M, Mclean H, Monto AM, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM.

Use of influenza antiviral agents by ambulatory care clinicians during the 2012-13 influenza season.

Clin Infect Dis. 2014 Jul 16. pii: ciu422. [Epub ahead of print].

Osterholm MT, Kelley NS, Belongia EA, Jackson LA, Jackson ML.

Reply: Cochrane rearranged.

Vaccine. 2014 Feb 13. pii: S0264-410X(14)00160-1. doi [Epub ahead of print]. PubMed


GHRI In the Media

Flu season never ends for Group Health researchers

Flu vaccine could be less effective this year

KING 5, December 4, 2014

Feature story

How safe is receiving Tdap vaccine during pregnancy?

JAMA study shows no raised risk for preterm birth or low birthweight in Vaccine Safety Datalink.

Featured video


Dr. Michael Jackson studies how to make vaccines safe and effective

Live Healthy

Vaccines:  Benefits outweigh the risks

vaccines, infectious diseases